Bioequivalence study of BHV-0223 in patients with amyotrophic lateral sclerosis

Trial Profile

Bioequivalence study of BHV-0223 in patients with amyotrophic lateral sclerosis

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Riluzole (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Oct 2017 According to a Biohaven Pharmaceutical media release, this study is expected to begin in the fourth quarter of 2017.
    • 12 Jul 2017 Based on the results of this trial, the company expects to submit an NDA for BHV-0223 for ALS in 2018 according to a Portage Biotech media release.
    • 16 Jun 2017 According to a Biohaven Pharmaceutical media release, this study is planned to launch in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top